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Introduction
Many mathematical models have been developed to describe
the dynamics of HIV replication under antiretroviral treatment
(ART) and the emergence of resistant mutants. ART has
frequently been shown to reduce the viral load to undetectable
levels, but ART regimens are complex and difficult to adhere to,
and the drugs are toxic with long-term side effects (see e.g.
refs 1–8.).
Structured treatment interruptions (STIs), that is, periodic
(cyclical) interruptions in ART, are being explored as an alterna-
tive strategy to continuous ART, as, in addition to reducing side
effects, they may also serve to boost HIV-specific immune
responses (see e.g. refs 9–11). Nevertheless, STIs also carry the
serious risk of improper viral control. Long periods without
treatment allow the viral population to grow, potentially causing
too much ‘stimulation’, leading ultimately to immune system
deterioration and AIDS.
In this paper we explore viral strain dynamics by developing a
mathematical model that includes a simple viral life cycle, the
effects of periodic treatment (including interruptions) and an
immune system response in the form of cytotoxic T-lympho-
cytes (CTLs). We derive new conditions to characterize the
dynamics of this system under conditions that simulate possible
STI strategies.
The paper is organized as follows: We first provide a brief
analysis of the basic model of HIV infection. Next, we extend the
analysis to include two viral strains and treatment with a reverse
transcriptase inhibitor (RTI), possibly with STIs. We investigate
the stability of the steady states and establish a condition for a
switch between the dominance of the two strains of HIV. This
demonstrates how the treatment interruptions relate to drug
resistance in this model. Finally, we include an immune sys-
tem response (in particular of CTLs) and explore how CTL level
varies under the influence of the STI. The appendix contains
proofs for the propositions presented in the body of the paper.
The basic model of HIV infection with reverse
transcriptase inhibitor
HIV is an RNA virus. When it infects a cell, the enzyme reverse
transcriptase (RT) makes a DNA analogue of its RNA genome,
which is integrated into the DNA of the infected cell. RTIs reduce
infection by inhibiting the action of reverse transcriptase. A
model that accounts for the action of an RTI is (see e.g. refs
12–14).
where T denotes the population of uninfected/target cells
(mostly CD4+ T cells), Y represents the population of infected
cells, and V the virus particle (virion) population. Here it is
assumed that target cells are created at a constant rate , die at a
rate d per cell and are infected at constant mass action rate k,
under perfect mixing of healthy and infected cells. Infected cells,
Y, die at a rate δ per cell and virions are produced by productively
infected cells. The form of the equations assumes that on average
each productively infected cell produces N virions during its life-
time. Free virions are assumed to be cleared at rate c per virion.
The efficacy of the RTI is captured by ε; if ε = 1, the inhibition is
100% effective, whereas if ε = 0, there is no inhibition.
Using the method of linearization and the Ruth-Hurwitz crite-
rion, one can easily show that depending on the efficacy of the
parameters, either the system eliminates the virus or the viral
load will stabilize at a non-zero steady state.
Accounting for two strains of HIV and structured
treatment interruptions
In the previous model, only one strain of virus was considered.
In reality, chemical ‘errors’ occur in the HIV life cycle (especially
during transcription between RNA and DNA), leading to differ-
ent strains of HIV, Vi . A target cell which is infected by the strain i
is denoted by Yi . Numerous mathematical models for HIV infec-
tion that account for more than one strain have been developed
(see e.g. ref. 3). A model accounting for two strains is as follows:
where εi(t) represents the efficacy of the drug on the strain Vi and
ηi is the rate of mutation of the strain Vi . The infection and viral
production rates are also allowed to vary between strains.
In dynamical models of infection, whether of individuals or
cells, it is usually instructive to obtain expressions for the basic
reproductive number (R0), which is the average number of new
infections spawned by a single infected individual (or cell)
inserted into an otherwise healthy population. In the case of a
constant drug efficacy (εi(t) = εi ), we have
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We develop a model of HIV infection with two viral strains, a
cytotoxic T-lymphocyte (CTL) response and structured treatment
interruptions. We derive new analytical relations characterizing the
dynamics between drug-sensitive and drug-resistant variants of the
virus, and the strength of the CTL response.
where
and
with k ki i i’ = −( )1 ε . Moreover:
1) If R0 < 1, then system (2) has only one steady state, the virus-
free steady state, (d , , , ,0 0 0 0) which is locally asymptotically
stable.
2) If R0 > 1, then the virus-free steady state becomes unstable
and system (2) has one additional steady state, the infected
steady state.
When two viral strains are not identical, it would require fine
tuning of the underlying parameters to obtain equal values for
R01’ and R02’ . So the natural case is R01’  R02’ and then the infected
steady state is given by
If the underlying parameters for the two strains are somehow
adjusted to give R01’ = R02’ , then the equilibrium condition is
given by
Let V1
0 and V2
0 be the values of V1 and V2 at the equilibrium
in the absence of RTI therapy. Under the influence of RTI ther-
apy, there will be a switch between the two strains if [(V1
0 –V2
0)
(V1 –V2 ) ≤ 0] with ((V1 ≠V2 ). We obtain a precise necessary and
sufficient condition for this switch between the two strains.
Denote
where j = 2 if i = 1 and j = 1 if i = 2.
~
R i0 (conversely
~’R i0 ) repre-
sents the basic reproductive number of strain i, accounting
for mutations, but without treatment (conversely under RTI
treatment). To talk clearly about a switch between two condi-
tions, we assume that R R01 02’ ’≠ and
~’ ~’R R01 02≠ . There is a switch
between the two strains if and only if
If we consider a treatment with periodic efficacy, system (2) has
only one steady state, the virus-free steady state, (d , , , ,0 0 0 0).
Assume that εi(t) is periodic and is given by a finite Fourier series:
where εi is the mean value of εi(t). Denote by R0 the basic repro-
ductive number of the averaged system of (2) (i.e. calculated for
ε εi it( ) = , the mean value of εi(t)). In this case, R0 is given by Equa-
tion (3) where εi is replaced by εi . The following result holds: If
R0 > 1, then the virus-free steady state is unstable.
If R0>1, the extended system of (2) (see appendix) has an
infected steady state which corresponds to the infected steady
state of the averaged system (2) (i.e. εi(t) replaced by εi ). Numerical
evidence shows that this steady state is stable.
We now give an explicit condition for the switch between the
two strains in terms of the efficacy of RTI. We adopt the form
εi(t)=εi(t), where εi represents the strain-specific efficacy of RTI
and (t) is a periodic function representing the (strain independ-
ent) level of RTI therapy. This naive ‘pharmokinetic’ model
should only be interpreted for physically sensible values of (t)
(i.e. between 0 and 1). Consider the regime
~ ~
R R01 02≥ . The condi-
tion for the switch is
~’ ~’R R01 02< , which is equivalent to
Assume that the concentration, 1(t), of an RTI, following a
single dose can be represented by a generic rise and fall as in
Fig. 1. For convenience, we define S+= a
a d+
(s)ds as the area
under the concentration curve where the level of drug is above
what the regimen aims to maintain outside of drug holidays.
Similarly, we define S1
− = 
0
a
(s)ds and S 2− = a d
b
+
(s)ds to decom-
pose the area under this curve into convenient pieces as building
blocks for the periodic case. If we consider a treatment with STIs
consisting of n successive doses at equal intervals of time,
followed by a period of drug holiday of length Loff, we obtain a
form for 1(t) as in Fig. 2. The mean value of this function is given
by
We can now give the switch condition in terms of the length of
the drug holiday, namely L Loff off
crit< , where
Treatment naturally applies selective pressure on the combined
system of the two strains. This condition shows the critical value
for the length of the drug holiday below which the STIs will
select for drug resistance, in the sense that the resistant strain
population exceeds the wild-type viral population. One must
consider further details of all the parameters to be able to decide
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Fig. 1. RTI level ε1(t ) for a single dose.
Fig. 2. RTI level ε(t ) with periodic doses and interruptions.
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when this is clinically problematic. In the limit of infinite inter-
ruptions (i.e. no treatment), there is a tiny drug-resistant popula-
tion, but also no viral control. In the limit of highly effective
continuous treatment, there is strong viral suppression (perhaps
even viral elimination, if R0 can be reduced below unity) but the
largest sub-population of any remaining virions will be the
drug-resistant strain. We do not explore the intermediate
regimes in any more detail, as this is only a sensible exercise if
we can insert numerous parameter values realistically into
physically relevant regimes, and for the present model we
cannot do this. It should be noted that the present model is
simplistic in the sense that:
• There are only two strains, whereas in reality there are many
coexisting strains, and
• the mutation rate we are using is approximately realistic for
two strains which differ by a single point mutation. Important
pairs of strains in reality may have very low mutation rates,
which are not sensibly modelled by continuous dynamics,
since mutation events will be rare.
Thus, to explore the emergence of clinically observed drug
resistance further, substantially more complex models need to be
considered. One might then be able to demonstrate more
nuanced hypothetical patient histories, including the appearance
of multiple mutations from populations of inadequately
suppressed single-point mutants.
Including a CTL response
In this section we extend model (2) by inclusion of a population
of effector (E) CD8+ T cells, also known as cytotoxic T-lympho-
cytes. This cell population is stimulated into clonal expansion
in response to HIV infection (see e.g. ref. 15). We obtain the
following model:
where E denotes a constant source of effector cells, β(Y1 + Y2)
represents the reaction term to the target cell infection, (Y1 +
Y2) is the loss term due to the binding of effector cells to infected
cells, and δE is the clearance rate of effector cells. Using the same
analysis as in the previous section, we see that the basic repro-
ductive number of the averaged system associated with (9),
( ( ) )ε εi it = , is given by
where
and
with k ki i i’ ( )= −1 ε . Moreover, if R0 > 1, then the virus-free steady
state 

d E
, , , , ,0 0 0 0 Eδ
⎛
⎝⎜
⎞
⎠⎟ of (9) is unstable.
Unlike system (2), the investigation of infected steady states for
system (9) is quite complicated (it involves the roots of a polyno-
mial of 5th order). Nevertheless, one can use a perturbation
method to determine the infected steady states. In fact, since η1
and η2 are small (around 10
–6), one can determine the infected
steady states for η1 = η2 = 0. A straightforward investigation
shows that when R0 > 1 (η1 = η2 = 0), there exists a unique
infected steady state
~
E0 (we do not give its expression because we
do not need it in our analysis). By means of the implicit function
theorem, one can show that for η1 ≈ η2 ≈ 0, there exists an
infected steady state
~
E which is close to
~
E0.
From the last equation of (9), we see that the value of E at the
equilibrium is given by
Clearly, if R0 increases, so do Y1, Y2 and E .
Consider an RTI treatment with STI, εi (t) = εi(t). In order to
increase R0, one needs to decrease the mean value of (t), which
can be achieved by increasing the length of the drug holidays.
Thus, STIs can be used to boost the CTL response by increasing
the length of the drug holidays; however, the length of this
period must not be so long that loss of viral control results.
Uncontrolled viremia will clinically lead to immune system
degradation, as well as the more complex viral evolution scenar-
ios already mentioned following Proposition (8), neither of
which can be demonstrated in a simple model like ours.
Finally, we adapt the threshold for the switch to having the
resistant viral population outnumber the wild type, which is
now given by
where
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Appendix
Proof of the basic reproductive number and stability analysis for sys-
tem (2): A steady state ( , , , , )T Y Y V V1 2 1 2 of (2) is the solution of
The last equation of (11) implies that Vi =
N
c
i i
i
δ
Yi . By substituting this
into the second and third equations of (11), we obtain V1 = V2 = 0, or
I. If V1 = V2 = 0, then Y1 = Y2 = 0 and T2=

d , leading to the virus-free
steady state E0 = (d , , , ,0 0 0 0). To determine the basic reproductive
number of (2), we use the method described in Watmough and van den
Driessche.16 We obtain the expression (3).
II. If V1 = V2 ≠ (0, 0) , then χ( )T = 0 or equivalently
Solving this equation for T , we obtain two solutions:
T – is always positive andT + is positive if and only if 1 – η1 – η2 > 0. For
T T= ± system (9) is equivalent to
or equivalently
Either 1 – η1 – η2 ≤ 0, in which case T
+ is negative, or 1 – η1 – η2 > 0, in
which case
This, together with (12), implies that ((R R01 02’ ’− )
2V V1 2
+ + ≤ 0). In either
case we obtain an unphysical steady state. If T = T – , we have
We distinguish two cases, R R01 02’ ’≠ and R R01 02’ ’= .
II.I. If R R01 02’ ’≠ , then
We claim that if R0 > 1 then V1 and V2 are positive. For this, we show
that
In fact, we have
A straightforward calculation shows that
If R01’ < R02’ , then
This implies that R01’ < R0 < R02’ . Similarly, we show that R02’ < R0 <R01’
if R02’ < R01’ .Therefore, condition (14) is satisfied and consequentlyV1 ,V2
are positive if R0 > 1.
II.2. If R01’ = R02’ , then, R0 = R01’ = R02’ . In this case system (9) is equiva-
lent, for T = T – , to
This implies that V
d R
k1
2 0
1 1 2
1
=
−
+
η
η η
( )
’( )
and V
d R
k2
1 0
2 1 2
1
=
−
+
η
η η
( )
’( )
.
Proof of (7), the condition for a switch between strains: If R’01< R’02 ,
then R01< R0 < R02’ . Therefore, V1
– < V2
– if and only if
That is,
or equivalently
Taking the square of both sides and simplifying, we obtain
Then
This implies that
Since R’02 – R’01 > 0, then
This is equivalent to
~’R01<
~’R02 . Similarly, we show that if
~’R01 >
~’R02 , then
V1
– < V2
– if and only if
~’R01<
~’R02 .
In the same manner as above we obtain that V1
0 < V2
0 if and only if
~’R01<
~’R02 , where V1
0 and V2
0 denote the values of V1 and V2 at the equilib-
rium before initiation of RTI. With this, condition (7) becomes a straight-
forward formulation of the switch condition in terms of the basic
reproductive numbers.
Proof that the virus-free steady state of system (2) is unstable when
R0 > 1: System (2) is a non-autonomous system. We transform it into an
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autonomous system by setting u t j si j i, ( ) cos ( )= ω and v t j si j i, ( ) sin( )= ω ,
for j = 1,…, n, and adding the auxiliary equations satisfied by (ui,j , vi,j). We
obtain
where i = 1, 2 and j = 1…n; and
and
System (16) has two steady states, which correspond to the steady
states of the averaged system of (2). Using the method described in
Watmough and van den Driessche,16 we calculate the basic reproductive
number, R0 , which is exactly the basic reproductive number, (3), of the
averaged system of (2) [calculated for ε εi it( ) = , the mean value of εi t( )].
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